Industry
Biotechnology
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Loading...
Open
2.87
Mkt cap
5.7M
Volume
139K
High
3.02
P/E Ratio
-0.26
52-wk high
17.75
Low
2.83
Div yield
N/A
52-wk low
1.16
Portfolio Pulse from Benzinga Insights
October 17, 2024 | 12:10 pm
Portfolio Pulse from Avi Kapoor
October 17, 2024 | 9:39 am
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 7:22 pm
Portfolio Pulse from Avi Kapoor
October 16, 2024 | 6:53 pm
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
October 16, 2024 | 4:26 pm
Portfolio Pulse from Avi Kapoor
October 16, 2024 | 2:03 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 2:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.